Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional Non-Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
10-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea real-time automatically updated data warehouse in health care (UNIVERSE - ROOT study).

Keunchil Park

8536

A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators.

Bo Cheng

e20014

Alteration in tumor immune microenvironment after chemo-radiotherapy for locally advanced non-small cell lung cancer.

Kazue Yoneda

8530

Association between smoking status and lymph node metastasis in Chinese patients with T1 non-small cell lung cancer: A real-world observational study.

Feng Jiang

e20012

Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC.

Fotinos-Ioannis D. Dimtrakopoulos

8537

Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.

Meaghan Dendy Case

8545

Blood-based TMB detection and dynamic monitor in local advanced non-small cell lung cancer (NSCLC) patients.

Xi Yang

e20039

Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer (NSCLC)?

Koichi Ogawa

e20017

Can steroid imbalance in intracrine synthesis of sex hormones in the lung be a pathognomonic factor of lung cancer?

Valeria A. Bandovkina

e20020

Characterizing biomarker testing over time in lung cancer patients using oncology electronic medical records (EMR).

Jennifer Christian

e20056

Clinical and prognostic implications of sarcopenia in patients affected by locally advanced NSCLC.

Sabrina Rossi

e20046

Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial.

Sayedmohammad Hasheminasab

8543

Comprehensive genomic profiling in Chinese patients with lung squamous cell carcinoma.

Zuping Lian

8540

Contemporary patterns of racial/ethnic disparities in surgical treatment and overall survival for localized resectable non-small cell lung cancer in the United States.

Oladimeji Akinboro

e20057

Correlation of tumor mutational burden, tumor microenvironment and alterations of driver genes in patients with NSCLC: A retrospective analysis.

Yao Yu

e20019

DIPNECH: The Mayo experience.

Daniel Almquist

e20029

Ectopic prolactin production by lung cancer cells as an indicator of aggressive nature of tumors.

Vladislav M. Legostaev

e20021

Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC).

Ning Li

8531

EGFR L858R mutation as a possible target for individual-independent immunotherapy in Chinese population.

Yu Chen

8538

Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FDG-PET staging.

Clare Senko

e20045

Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).

Yi-Long Wu

TPS8572

Genetic profiling of synchronous multiple primary lung carcinomas presenting as ground-glass opacities.

Fenglei Yu

e20034

Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients.

Raquel Laza Briviesca

e20026

Identification of MET Exon 14 skipping by targeted RNA-based next-generation sequencing in Chinese Patients with NSCLC.

Nanying Che

e20018

Identifying actionable somatic mutations in lung cancer using cell-free DNA from bronchial washing fluid.

Xin Zhang

8528

Immune landscape of the tumor microenvironment to predict prognosis and DNA mutations in patients with lung adenocarcinoma.

Sunyoung S. Lee

8544

Impact of invasive regional lymph node examination (IRLNE) and time to radiation on overall survival for patients with stage I NSCLC treated with SBRT- a NCDB analysis.

Pradnya Dinkar Patil

e20041

Impact of resectable lung adenocarcinoma pathological subtypes on patients prognosis and surgical strategies determination: A SEER population-based data analysis.

Di Lu

e20035

Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).

Theodoros Tsakiridis

8502

Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.

Melissa Yan

8535

Longitudinal tumor size and NLR as predictive factors of individual survival compared to their baseline values in patients with non-small cell lung cancer treated with durvalumab.

Kirill Zhudenkov

e20047

Lung cancer diagnosed by an incidental lung nodule program or lung cancer screening.

Matthew Smeltzer

8546

Mutation concordance of matched tissue sample and blood sample: A result of 456 lung cancer patients.

Xiaoping Wen

e20049

Mutational landscape of early-stage non-small cell lung cancer patients using a 451 gene panel.

Guanxian Mao

e20048

Mutational landscapes and PD-L1 expression in non-small cell lung cancer.

Kang Zhang

8541

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

David J. Kwiatkowski

8503

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.

Mariano Provencio

8509

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

Tina Cascone

8504

Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response.

Joshua E. Reuss

8524

Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223.

Jair Bar

8534

Neutrophil-to-lymphocyte ratio and subsequent recurrence of non-small cell lung cancer patients in remission.

Abigail Sy Chan

8533

Oncogenic activation of the HRR pathway drives RAD54L expression in early stage lung adenocarcinoma.

Shaopeng Zheng

e20037

Oncologic outcomes of segmentectomy versus lobectomy for radiologically aggressive small-sized lung cancer.

Atsushi Kamigaichi

8525

Outcomes among patients with a history of substance abuse in non-small cell lung cancer: A county hospital experience.

Kyle Concannon

e20031

Outcomes following lobectomy and pneumonectomy in stage IIIA non-small cell lung cancer (NSCLC) after neoadjuvant chemoradiation.

Anuhya Kommalapati

e20042

PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC.

Jeffrey D. Bradley

TPS8573

Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.

Salma K. Jabbour

TPS8575

Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer.

Steven H. Lin

8512

Postoperative radiotherapy for stage II or III non–small cell lung from 1988 to 2014.

Dawei Chen

e20013

Preoperative lymph node assessment in surgically resected pathologic T1 lung cancer patients: Real world clinical practice in China.

Xu Jinming

e20016

Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer.

Salma K. Jabbour

8511

Randomized phase Ⅱ trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage Ⅲ non-squamous non-small-cell lung cancer: NJLCG1001.

Kana Watanabe

8527

Report of four cases of pulmonary malignant tumors treated with SBRT using BODYFIX plus 4D-CBCT image guidance technique.

Lei Wu

e20050

Retrospective study of capecitabine and temozolomide in advanced lung neuroendocrine neoplasms.

Taymeyah E. Al-Toubah

8542

S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).

Athanassios Argiris

8523

Selection of patients for stereotactic body radiation therapy (SBRT) or (bi)lobectomy (L) for the treatment of cT1-T2N0M0 NSCLC by the risk of node involvement using readily available preoperative factors.

Molly Griffin

e20055

T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).

Alexandre Reuben

8532

The cross talk between the molecular alterations and tumor immunity in the microenvironment in non-small-cell lung carcinoma.

Chengzhi Zhou

e20043

The impact of heart radiation dose in lung SABR.

Hao Wen, Gerald Gan

e20054

The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma.

Luwei Tao

e20022

The relative impact of patient and institutional rurality on lung cancer disparities.

Meredith Ray

e20052

The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT).

Nitin Ohri

TPS8571

The spatiotemporal evolution of early-stage non-small-cell lung cancer.

Siwei Wang

8539

Three-year overall survival update from the PACIFIC trial.

Jhanelle Elaine Gray

8526

Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).

Luis G. Paz-Ares

TPS8574

Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: A validation study in Chinese patients.

Chen Chen

8522

Umbrella study of anticancer agents in Chinese patients with NSCLC.

Xin Zhao

e20044

Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.

Atsushi Horiike

8529

Use of surgery and stereotactic body radiotherapy (SBRT) in very elderly patients with early-stage non-small cell lung cancer (NSCLC): A national cancer database (NCDB) analysis.

Michael Kharouta

e20058

Value of precision medicine in advanced NSCLC: Real-world outcomes associated with the use of companion diagnostics.

Ani John

e20015

Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07).

David E. Kozono

8510

When is a patient high risk for resection? A changing paradigm with minimally invasive lung surgery.

Hiroko Nakahama

e20059